Natural history study and clinical evaluation of an RNA therapy for SCA1

This study investigates new treatments that target the toxic ataxin-1 protein. We want to achieve this by binding a so-called ‘antisense oligonucleotide’ (ASO) to the ATXN1 messenger molecule. The ASO will block the messenger molecule, which will hinder the production of the ataxin-1 protein. We expect that this will limit brain damage in patients with SCA1, as well as slowing and diminishing disease progress. If this project succeeds, this is a major breakthrough not only for patients and families suffering from SCA1, but also for other forms of SCA.
WHAT WE DO?
The SCA1 study consists of 3 parts
Documents for patients
Video explaining SCA1
Video SCA1 research: online meeting January 2021
Information letters
Information papers for SCA1 mutation carriers can be downloaded by clicking the button below.
Frequently Asked Questions (FAQ)
Publications
List of services
-
Hommerson et al, 2021List item 1Literature review on various studies on mimicking different types of ataxia with cells from patients. These insights can be used to learn more about the mechanism of the disease. This is relevant for testing new drugs.
-
Buijsen et al, 2019List item 2Literature review on SCAs that are caused by a CAG repeat in the DNA. This concerns SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17. How often does the disease occur in certain areas and what causes the disease? What are the differences and similarities between these diseases and how can we learn from this to develop therapies.
-
Kourkouta et al, 2019List item 3In this study, the candidate drug was tested in SCA1 models.
-
Buijsen et al, 2018List item 4In the preliminary phase of this research, we collected skin cells from SCA1 patients and healthy family members and made stem cells from them. These stem cells were used for further research into the candidate drug.